Loading ...
Sorry, an error occurred while loading the content.
 

Triple Antiviral Therapy as a New Option For Patients With Interferon Nonresponsive Chronic Hepatitis C

Expand Messages
  • claudine intexas
    **This article can be viewed in it s entirety (5 long pages!) at Hepatitis-Central (must have Adobe Acrobat Reader) Triple Antiviral Therapy as a New Option
    Message 1 of 1 , Aug 28, 2000
      **This article can be viewed in it's entirety (5 long
      pages!) at Hepatitis-Central (must have Adobe Acrobat
      Reader)


      Triple Antiviral Therapy as a New Option for Patients
      With Interferon Nonresponsive Chronic Hepatitis C

      Hepatology Sept. 2000; 32: 630-634

      Stefano Brillanti, Fabio Levantesi, Livia Masi, Mauro
      Foli, and Luigi Bolondi

      The aim of the study was to evaluate the efficacy of
      triple antiviral therapy with interferon,
      ribavirin, and amantadine in comparison with
      interferon and ribavirin combination treatment in
      patients with interferon-nonresponsive chronic
      hepatitis C. We performed an open-label, prospective
      randomized controlled trial at a secondary referral
      center. We used a 2:1 ratio, patients received
      interferon, ribavirin, and amantadine, or interferon
      and ribavirin for 12 months, and were followed up for
      an additional 6 months. Ninety-four consecutive adult
      interferon nonresponders with chronic hepatitis C were
      screened. Sixty consecutive elected patients entered
      the study. No patients withdrew because of adverse
      events. Forty patients received interferon alfa (5
      megaunits on alternate days), ribavirin (800 - 1000 mg
      daily), and amantadine (200 mg daily) for 12 months,
      and 20 patients received the same treatment without
      amantadine. At the end of follow-up, alanine
      transaminase (ALT) level normalization was maintained
      in 23 of 40 patients (57%) after triple therapy, but
      in 2 of 20 patients (10%) after double therapy
      (P<.001, RR = 2.11, 95% CI, 1.43 - 3.12), whereas
      disappearance of serum HCV RNA persisted in 19 of 40
      patients (48%) and in 1 of 20 patients (5%),
      respectively (P< .001, RR = 1.81, 95% CI, 1.32 -
      2.47). The safety profile was similar in the 2 groups.
      In conclusion, in patients with
      interferon-nonresponsive chronic hepatitis C, triple
      antiviral therapy for 1 year results in a high rate of
      sustained biochemical and virologic responses.

      =====
      Claudine
      claudinecrews@...

      __________________________________________________
      Do You Yahoo!?
      Yahoo! Mail - Free email you can access from anywhere!
      http://mail.yahoo.com/
    Your message has been successfully submitted and would be delivered to recipients shortly.